Although the therapeutic approach to managing hyperparathyroidism has changed dramatically, it is unknown whether parathyroidectomy rates continue to decline in the United States. Parathyroidectomy rates were studied in successive annual national cohorts, prevalent on hemodialysis on January 1 of 1992 to 2002, with Medicare as primary payer. Parathyroidectomy was defined as International Classification of Diseases, Ninth Revision, Clinical Modification code 068. The annual incidence of parathyroidectomy was 11.6 per 1000 patient-years in 1992. The incidence declined progressively after 1994, reaching a low of 6.8 per 1000 patient-years in 1998. Rates increased progressively after 1998, reaching 11.8 per 1000 patient-years in 2002. Using proportional hazards modeling, with adjustment for comorbidity and 1992 as the reference group, the lowest adjusted hazards ratio, 0.32 (P < 0.0001), was seen in 1998, followed by hazards ratios of 0.39 (P < 0.0001) in 1999, 0.41 (P < 0.0001) in 2000, 0.52 (P < 0.0001) in 2001, and 0.53 (P < 0.0001) in 2002. Other antecedents of parathyroidectomy in multivariate models included ESRD network, younger age, female gender, white race, absence of diabetes, longer duration of previous hemodialysis, use of intravenous vitamin D, previous renal transplantation, several comorbid conditions, and parathyroid hormone measurement in the preceding year. With a case-control method, parathyroidectomy was associated with higher mortality rates immediately after surgery, followed, subsequently, by lower long-term rates. Parathyroidectomy rates in U.S. hemodialysis patients increased between 1998 and 2002, a period in which the therapeutic armamentarium for preventing severe hyperparathyroidism expanded considerably.
B
one disease and abnormalities of calcium phosphorus homeostasis are common in patients with advanced chronic kidney disease. Bone disorders in these patients are often classified into two major types, low turnover and high turnover, the latter associated with high parathyroid hormone (PTH) levels (1, 2) . In the past decade, the management of hyperparathyroidism has changed dramatically. The therapeutic armamentarium for preventing severe hyperparathyroidism continues to expand and includes proactive detection strategies, manipulation of calcium and phosphate input and output, administration of phosphate binders, therapy with vitamin D sterols, and effective uremic toxin removal (3) . In a time when effective treatment strategies are increasingly available, parathyroidectomy could be viewed as indicating a medical failure, as the procedure may have implications in terms of morbidity, mortality, and utilization of resources.
Materials and Methods
Among U.S. hemodialysis patients who were receiving dialysis on January 1 of the years 1992 to 2002, our objectives were to (1) compare incidence rates of parathyroidectomy by calendar year (our primary objective), (2) describe additional demographic and comorbid factors associated subsequently with parathyroidectomy, and (3) estimate mortality risks associated with parathyroidectomy.
Patients
We studied patients who had Medicare as primary payer and were receiving hemodialysis in the United States on January 1 of each of the years from 1992 to 2002. Demographic and baseline characteristics at initiation of dialysis, including age, gender, race, and primary renal diagnosis, were obtained from the Identification and Medical Evidence portions of the Renal Beneficiary Utilization System of the Centers for Medicare & Medicaid Services. Data on comorbid conditions were derived from Medicare Part A and Part B claims, between dialysis initiation and January 1 of that year; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Physicians' Current Procedural Terminology (CPT) codes were used for this purpose. Intravenous vitamin D use was determined from Medicare Part A outpatient files, using Healthcare Common Procedure Coding System codes J0635 and J2500 for calcitriol and paricalcitol, respectively. Parathyroidectomy occurrence was determined from Medicare Part A inpatient claims, using ICD-9-CM code 068. Data on PTH measurement were obtained from Medicare Part A outpatient and Part B physician files, using CPT code 83970.
for each point-prevalent group was from January 1 of that year to the earliest of the following in the same year: parathyroidectomy, death, or December 31. Cox regression was the primary analytical technique used, with time to parathyroidectomy as the outcome variable. The exploratory variables included the point-prevalent year, as well as age, gender, race, primary renal diagnosis, comorbid conditions, years of hemodialysis, use of intravenous vitamin D, previous parathyroidectomy, previous renal transplantation, and PTH measurement in the preceding year. We reasoned that differences in transplantation rates could confound annual parathyroidectomy rate comparisons and therefore chose to use two different analytical approaches. In model 1, transplantation was not used as a censoring event; in model 2, it was.
We used a case-control design, performed in two separate eras (1994 to 1995 and 1998 to 1999), to estimate the association between parathyroidectomy and mortality. Our findings were similar, regardless of whether censoring was performed at renal transplantation, and only findings with the latter method are presented here. In the 1994 to 1995 analysis, the study sample consisted of patients who were receiving hemodialysis on January 1, 1994, with no history of parathyroidectomy in the preceding 2 yr. Cases were defined as any patient who underwent parathyroidectomy between January 1, 1994, and December 31, 1995; control subjects were defined as those who did not undergo parathyroidectomy during the same period. Patients were characterized, and follow-up began on the day of parathyroidectomy for cases and January 1, 1995, for control subjects. Follow-up ended at death, parathyroidectomy in the follow-up period, or December 31, 2002. Poisson regression, in 3-mo intervals, was used to estimate the relative risk of death of cases, compared with control subjects, with adjustment for the following variables: age, gender, race, cause of ESRD, time elapsed since inception of renal replacement therapy, ESRD network, use of vitamin D in the preceding year, PTH measurement in the preceding year, comorbid conditions, and previous renal transplantation. The 1998 to 1999 analysis was identical to the 1994 to 1995 analysis, except that cases and control subjects were defined 4 yr later. Table 1 provides baseline characteristics of the complete study population and includes a comparison of the 1992 to 1996 and 1997 to 2002 groups. On logistic regression, the 1997 to 2002 cohort differed from the earlier cohort in terms of network and years spent on hemodialysis. In addition, the 1997 to 2002 cohort was more likely to be older, be male, have race categorized as white or other, have diabetes as primary cause of ESRD, use intravenous vitamin D, have comorbid conditions, and have had a PTH measurement in the preceding year. The 1997 to 2002 cohort was less likely to have had a previous renal transplantation or parathyroidectomy. Figure 1 shows that parathyroidectomy rates in each of the years from 1992 to 2002 were related to duration of previous hemodialysis therapy. Figure 1 also shows that overall parathyroidectomy rates, estimated at 11.6 per 1000 patient-years in 1992, progressively declined to a low of 6.8 per 1000 patientyears in 1998. Rates increased after 1998, reaching 11.8 per 1000 patient-years in 2002. Similar trends were seen when patients were categorized by duration of previous hemodialysis. Table 2 reports parathyroidectomy rates and adjusted hazards ratios according to baseline patient characteristics. With proportional hazards modeling, using 1992 as the reference group, the lowest adjusted hazards ratio, 0.32 (P Ͻ 0.0001), was seen in 1998, followed by hazards ratios of 0.39 (P Ͻ 0.0001) in 1999, 0.41 (P Ͻ 0.0001) in 2000, 0.52 (P Ͻ 0.0001) in 2001, and 0.53 (P Ͻ 0.0001) in 2002. Parathyroidectomy rates varied substantially across the ESRD networks, with Network 18 (the southern counties of California) exhibiting the lowest and Network 16 (Alaska, Idaho, Montana, Oregon, and Washington) exhibiting the highest rates. Parathyroidectomy rates were notably higher in patients of longer dialysis vintage and lower among those with a previous parathyroidectomy. Other associations of parathyroidectomy in multivariate models included younger age, female gender, white race, absence of diabetes, use of intravenous vitamin D, several comorbid conditions, previous renal transplantation, and PTH measurement in the preceding year. In Table 2 , it is worth noting that unadjusted event rates were substantially greater for black patients than for white patients. The inversion of the hazards ratio in the adjusted model suggests that racial associations of parathyroidectomy were considerably modified by the other variables used in the adjustment procedure. A similar situation existed for the variable congestive heart failure. Figure 2 summarizes adjusted relative risk of death after parathyroidectomy when a case-control method was applied in the 1994 to 1995 and 1998 to 1999 periods. Biphasic mortality associations were present in both analyses, with an increased relative risk of death in the initial 3 to 6 mo after parathyroidectomy, followed by a lower risk estimate in subsequent intervals.
Results

Discussion
We found that annual parathyroidectomy rates progressively declined in the United States from 1992 to 1998 but successively increased in 1999, 2000, 2001, and 2002. Temporal trends in incidence rates were similar with use of comorbidity-adjusted analyses. Parathyroidectomy rates varied substantially across the ESRD networks. Other associations of parathyroidectomy included younger age, female gender, white race, cause of ESRD other than diabetes, longer duration of previous hemodialysis, and use of intravenous vitamin D. Parathyroidectomy was associated with a biphasic mortality pattern, with adjusted risks increasing in the first 3 to 6 mo after surgery, followed by lower risks in the ensuing intervals.
Parathyroidectomy rates are often used as a barometer of management success or failure in large populations of dialysis patients. One national-level study found that the proportion of prevalent ESRD patients who underwent parathyroidectomy in the United States declined significantly from 1988 to 1998 (4). Another recent national-level study found an overall decline in parathyroidectomy rates between 1990 and 1999; as found in our study, rates were lowest in 1998 (5). Although our study showed similar trends, it differed in several ways from other studies: We used 2000, 2001, and 2002 as prevalent years, excluded peritoneal dialysis patients, included patients with previous parathyroidectomy and renal transplantation, assessed a wide range of comorbidity, and restricted follow-up to a maximum of 1 yr in each prevalent cohort. Our approach to follow-up was intended to equalize the potential duration of follow-up in each annual cohort, given our belief that parathyroidectomy rates would likely increase with longer follow-up.
Outside the United States, the Okinawa Dialysis Study reported that parathyroidectomy rates were lower in the 1980s than in the 1970s (6). The European Dialysis and Transplantation Association Registry reported several years ago that the proportion of patients with a history of parathyroidectomy increased between 1982 and 1988; incidence rates of new parathyroidectomy were similar throughout this period (7) . Another large-scale study was that of Malberti et al. (8) , who reported findings on 14,180 patients who received renal replacement therapy between 1983 and 1996 in Lombardy. Incidence rates were relatively constant over time, unlike those in our study. Higher parathyroidectomy rates were associated with female gender, longer dialysis vintage, and use of peritoneal dialysis; younger age, diabetic nephropathy, and renal transplantation were associated with lower rates. The underlying basis for these associations, which mirror closely those found in our study, remains speculative. a Unadjusted rate of parathyroidectomy per 1000 patient-years. b In model 1, renal transplantation was not a censoring event. In model 2, renal transplantation was a censoring event. c Using Cox regression. The reference categories were: point-prevalent year, 1992; age, Ͻ45 yr; gender, male; race, white; cause of ESRD, diabetes; years of hemodialysis, Յ1; use of intravenous vitamin D, no; comorbid conditions, no (for each); previous parathyroidectomy, no; previous renal transplantation, no; PTH in preceding year, no.
d Networks: 1, Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont; 2, New York; 3, New Jersey, Puerto Rico, and U.S. Virgin Islands; 4, Pennsylvania; 5, District of Columbia, Maryland, Virginia, and West Virginia; 6, Georgia, North Carolina, and South Carolina; 7, Florida; 8, Alabama, Mississippi, and Tennessee; 9, Indiana, Kentucky, and Ohio; 10, Illinois; 11, Michigan, Minnesota, North Dakota, South Dakota, and Wisconsin; 12, Iowa, Kansas, Missouri, and Nebraska; 13, Arkansas, Louisiana, and Oklahoma; 14, Texas; 15, Arizona, Colorado, Nevada, New Mexico, Utah, and Wyoming; 16, Alaska, Idaho, Montana, Oregon, and Washington; 17, American Samoa, Guam, Hawaii, Saipan, and northern counties of California; 18, southern counties of California.
It is widely known that primary hyperparathyroidism occurs more frequently in women (9) , and it is possible that women with uremia are more susceptible to secondary hyperparathyroidism and/or renal bone disease. It has been reported by others that diabetic ESRD patients may have lower PTH levels than their nondiabetic counterparts and may be more susceptible to low-turnover bone disease (10, 11) . High-dose parenteral vitamin D is often attempted as a "final" nonsurgical strategy when parathyroidectomy is being considered (12) . The association between the use of parenteral vitamin D and subsequent parathyroidectomy may reflect hyperparathyroidism that was more advanced at the beginning of the outcome assessment period. We are unsure why parathyroidectomy rates decreased so dramatically with advancing age; patient selection factors and death as a competing risk may have been involved.
Parathyroidectomy rates were heterogeneous across large geographic areas. To our knowledge, few if any studies have examined this issue. A PubMed search on October 6, 2004, using the terms parathyroidectomy, geographic, and dialysis yielded no citations. The causes of such heterogeneity could not be determined from this observational study. Differences in prevalent case mix could account for some of the heterogeneity, as could approaches to management of bone metabolism. It was interesting that the lowest parathyroidectomy rates were seen in a region of relatively high population density (the southern counties of California), whereas the highest rates were seen in a region of relatively low population density (Alaska, Idaho, Montana, Oregon, and Washington). It is tempting to speculate that access to specialist nephrology care may partly account for some of the heterogeneity in parathyroidectomy rates.
We found biphasic associations between parathyroidectomy and mortality. Compared with patients who did not undergo the procedure, higher mortality rates were seen immediately after surgery, followed, in the longer term, by lower mortality rates. Mortality patterns were similar in the 1994 to 1995 and the 1998 to 1999 case-control analyses. It is difficult to unravel the relative contributions of unmeasured comorbid conditions and patient selection to these findings. One of many possible interpretations, however, includes the following hypothesis: Eradication of refractory hyperparathyroidism improves cardiovascular risk (as has been speculated for decades) but at a short-term cost (the risk associated with parathyroid surgery).
Typical textbook indications for parathyroid surgery include "the unequivocal evidence of secondary HPT [hyperparathyroidism] (very high levels of serum PTH and/or the presence of osteitis fibrosa on bone biopsy), together with any of the following: (1) (5) calciphylaxis" (13) . For a given severity of hyperparathyroidism, the decision to recommend parathyroidectomy often involves a careful balance of several factors. These include the likelihood of long-term survival on dialysis and transplantation, anesthetic risk, and the availability of appropriate surgical and radiologic services. The management of renal bone disease changed dramatically during the years included in this study. For example, assays that measure the intact PTH molecule became the norm (14) . Several active forms of vitamin D sterol became available, including some with a lower tendency to raise serum calcium levels for a given decrease in PTH levels; aluminum use became uncommon, largely supplanted by calcium-based phosphate binders and non-calcium-containing phosphate binders, such as sevelamer (15) (16) (17) (18) (19) (20) . It is likely that the declining rates of parathyroidectomy between 1992 and 1998 partly reflect these advances. The relatively sudden rise in parathyroidectomy rates after 1998 was unexpected.
Several obvious questions present themselves, not least of which is whether the trends observed are artifactual, a consequence of the methods used. Inclusion in this study was defined on the basis of dialysis use on January 1 of each calendar year, and follow-up was restricted to the ensuing 12 mo. We chose this model, as opposed to an incident model (in which all newcomers to hemodialysis in a calendar year are studied), because parathyroidectomy rates were expected to be very low initially. We attempted to characterize the patients extensively in each year, but it is possible that unmeasured factors could have changed from year to year. The study was based on administrative claims, and calcium, phosphorus, and PTH levels were not available. It thus is impossible to disprove the hypothesis that the trends observed in this study reflect changes in the threshold levels of hyperparathyroidism that triggered referral for surgery. The decision to recommend parathyroidectomy is heavily dependent on PTH levels; it is possible that changes in the assays used may have led to changes in PTH levels, leading to parathyroidectomy, without any real biologic changes in successive patient cohorts. Unfortunately, this hypothesis is not one that we can address directly from the data available to us. In practice, a single code is available for "parathormone," irrespective of the type of assay used. PTH was measured more frequently in later cohorts. It is conceivable, therefore, that the overall burden of diagnosed and undiagnosed severe hyperparathyroidism may have remained constant over time; in this scenario, the rise in parathyroidectomy rates in later years might reflect a rising proportion of diagnosed disease, offset by a declining proportion of undiagnosed disease. This being said, the same analytical methods were used for cohorts before and after 1998, and it is difficult to believe that methodologic flaws fully account for the biphasic trend in parathyroidectomy rates before and after 1998. It is also possible that heterogeneity of therapeutic approach accounts for some of our findings. If the recently introduced Kidney Disease Outcomes Quality Initiative guidelines (21) are embraced, then it is possible that harmonization of treatment practices could lead to lower parathyroidectomy rates. Finally, with large data sets, differences that are trivial from a clinical perspective can be associated with a high degree of statistical significance.
The trends seen in this study may reflect changing enthusiasm for the aggressive use of calcium-augmenting therapies between 1992 and 2002. This enthusiasm may have been tempered by the risk of low-turnover bone disease and the realization that extraskeletal calcium deposition may place patients at risk (22, 23) . If one argues that the risk of untreatable or autonomous hyperparathyroidism increases with higher PTH levels and longer exposure periods, then higher parathyroidectomy rates might be expected with less aggressive treatment practices. This speculation cannot be addressed directly using the findings of this study. Similarly, other possible explanations, such as the use of different PTH assays and the emergence of newer vitamin D sterols and phosphate binders, cannot be addressed. Large observational studies are relatively good for discerning trends but relatively poor for elucidating causal mechanisms. We believe, however, that the study suggests associations of clinical importance and establishes a reasonable foundation for monitoring future trends and initiating hypothesis-driven prospective studies to better understand observed trends. Despite its flaws, this study suggests a disturbing pattern: An unexplained recent rise in parathyroidectomy rates at a time when the therapeutic armamentarium for preventing severe hyperparathyroidism was expanding considerably.
